Cargando…
HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing
Background: With the approval of the HIV-1 capsid inhibitor, lenacapavir, capsid sequencing will be required for managing lenacapavir-experienced individuals with detectable viremia. Successful sequence interpretation will require examining new capsid sequences in the context of previously published...
Autores principales: | Tao, Kaiming, Rhee, Soo-Yon, Tzou, Philip L., Osman, Zachary A., Pond, Sergei L. Kosakovsky, Holmes, Susan P., Shafer, Robert W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143361/ https://www.ncbi.nlm.nih.gov/pubmed/37112972 http://dx.doi.org/10.3390/v15040992 |
Ejemplares similares
-
Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy
por: Tzou, Philip L., et al.
Publicado: (2018) -
Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons
por: Tzou, Philip L., et al.
Publicado: (2022) -
Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis
por: Tao, Kaiming, et al.
Publicado: (2022) -
Sierra SARS-CoV-2 sequence and antiviral resistance analysis program
por: Tzou, Philip L., et al.
Publicado: (2022) -
Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences
por: Tzou, Philip L., et al.
Publicado: (2020)